628298-58-8

Usage

Uses

3-Sulfamoylbenzylamine acts as a Schiff base in organic reactions.

InChI:InChI=1/C7H10N2O2S/c8-5-6-2-1-3-7(4-6)12(9,10)11/h1-4H,5,8H2,(H2,9,10,11)

Upstream product

• 3118-68-1 3-cyanobenzenesulfonamide 

Downstream Products

• 1520082-74-9 C₃₉H₄₉N₅O₉S 
• 1203655-69-9 3-{[6-chloro-4-(2,2,2-trifluoro-ethylamino)-pyrido[3,2-d]pyrimidin-2-ylamino]-methyl}-benzenesulfonamide 
• 918811-31-1 N-(3-sulfamoylbenzyl)-2-(1-(di-tert-butoxycarbonylamino)isoquinolin-6-ylamino)-2-(3-methylthiophenyl)acetamide 
• 918811-28-6 N-(3-sulfamoylbenzyl)-2-(1-(di-tert-butoxycarbonylamino)isoquinolin-6-ylamino)-2-(3-methoxyphenyl)acetamide 
• 918811-23-1 N-(3-sulfamoylbenzyl)-2-(3-bromophenyl)-2-(1-(di-tert-butoxycarbonylamino)isoquinolin-6-ylamino)acetamide 

Relevant academic research and scientific papers

TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS

The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

The present invention provides novel phenylglycinamide derivatives of Formula (I) or (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables W, W1, Y, Z, R7, R8, R9, and R11 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.